Please login to the form below

Not currently logged in
Email:
Password:

Zealand announces management changes

Firm making the roles of chief scientific officer and chief operating officer redundant

Zealand Pharma is set to make a series of restructuring changes that will shake-up a number of positions at the firm.  

The R&D arm of Zealand will be split into two parts, each with direct representation in management, while investor relations and communications will also be represented directly at management level.

As a result of the restructuring, the former positions of chief scientific officer and chief operating officer have become redundant.

Adam Steensberg, VP for development, has been promoted and appointed to the new position as senior VP for development and chief medical officer. 

The new position as senior VP for research will temporarily be filled by Keld Fosgerau, currently VP for research, while the company searches for a permanent appointment. 

Hanne Leth Hillman, VP for investor relations and corporate communications is promoted, and appointed to the new position as senior VP for investor relations and communications.

The reorganisation aims to “eliminate one management level in support of the company's strategy” and to “ensure a dynamic organisation with operational flexibility and short decision-making”.

Britt Meelby Jensen, president and CEO of Zealand, said: “I wish Adam, Keld and Hanne every success in their new roles and I look forward to working with them in their new roles.”

Article by
Ben Adams

20th March 2015

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
90TEN

90TEN is an award-winning healthcare communications consultancy that puts people at the heart of everything we do. Our Life.Changing. campaigns...

Latest intelligence

BRIC markets
BRIC markets
Why these countries offer an opportunity for pharma despite a slowdown...
Obstetrics Virtual Journal Club: An Impetus Digital Customer Success Story
Our online solutions are not just for advisory boards - find out how one client leveraged the Impetus InSite Platform® for a virtual journal club....
Ludovic Helfgott
Novo Nordisk awakens its ‘Sleeping Beauty’
Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...

Infographics